Skip to content
Screener

Xencor XNCR Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.29B+19.8%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$31.69M+29.8%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$62.78M-26.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.64M-25.8%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
-$10.8M-131%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+210%
Enterprise value$1.67B+150%
P/S14.7×+11.3×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development71,90561,665136,574120,243
General and administrative16,38415,11534,09332,452
Total operating expenses88,28976,780170,667152,695
Operating loss(37,068)(33,172)(114,930)(76,355)
Other income (expense):
Interest income4,8007,24810,25914,786
Interest expense(7,352)(8,243)(12,052)(16,908)
Gains (losses) on equity securities, net18,0644,967(33,865)5,908

Item 1. Financial Statements

FAQ

What is Xencor's operating income?
Xencor (XNCR) reported operating income of -$37.07M in Q2 2026.
How has Xencor's operating income changed year-over-year?
Xencor's operating income decreased by 11.7% year-over-year, from -$33.17M to -$37.07M.
What is the long-term trend for Xencor's operating income?
Over 4 years (2021 to 2025), Xencor's operating income has grown at a 41.9% compound annual growth rate (CAGR), from $43.77M to -$177.5M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Xencor's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude